secwatch.observer — SEC 8-K summary
======================================

Issuer:     SPRUCE BIOSCIENCES, INC. (SPRB)
CIK:        0001683553
Form:       8-K
Filed at:   2026-03-20T23:59:59+00:00
Accession:  0001193125-26-117888
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.02
LLM model:  deepseek-v4-flash:cloud@v2

Spruce terminates Kaken collaboration for tildacerfont in Japan; reports FY 2025 results, BLA on track
--------------------------------------------------------------------------------

- Termination of Collaboration and License Agreement with Kaken effective March 31, 2026; no penalties incurred.
- FY 2025 net loss $39.0M on operating expenses $36.5M; cash $48.9M excluding $15M debt tranche from Avenue Capital.
- BLA submission for TA-ERT (MPS IIIB) on track for Q4 2026; FDA confirmed potential for accelerated approval.
- Appointed Dale Hooks as Chief Commercial Officer; secured up to $50M loan facility from Avenue Capital Group.
- R&D expenses fell to $19.5M from $46.4M, driven by cessation of tildacerfont development for CAH.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1683553/000119312526117888/0001193125-26-117888-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1683553/000119312526117888/sprb-20260316.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-117888

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer